Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ATR | Q13535 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TOP1 | P11387 | 3/20 | 0.48 |
| ▸ | CYCS | P99999 | 3/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8994447 | 0.88 | TOP1 (0.60) | ALDH1A1HPGDHSD17B10NPC1RAB9A | |
| SCHEMBL7241022 | 0.87 | TOP1 (0.58) | ALDH1A1HPGDKDM4ESMN1; SMN2TOP1 | |
| SCHEMBL14077524 | 0.84 | ABCG2 (0.54) | ALDH1A1HPGDHSD17B10NPC1RAB9A | |
| SCHEMBL9910535 | 0.83 | ABCG2 (0.55) | ALDH1A1HPGDHSD17B10NPC1RAB9A | |
| SCHEMBL185112 | 0.81 | TERT (0.54) | ALDH1A1KDM4ETOP1CYCSCYP1A2 | |
| SCHEMBL29501072 | 0.81 | TERT (0.54) | ALDH1A1KDM4ETOP1CYCSCYP1A2 | |
| SCHEMBL29021355 | 0.80 | TERT (0.52) | ALDH1A1KDM4ETOP1CYCSCYP1A2 | |
| SCHEMBL21808804 | 0.80 | TERT (0.52) | ALDH1A1KDM4ETOP1CYCSCYP1A2 | |
| SCHEMBL30385992 | 0.80 | TERT (0.52) | ALDH1A1KDM4ETOP1CYCSCYP1A2 | |
| SCHEMBL2423305 | 0.80 | TERT (0.52) | ALDH1A1KDM4ETOP1CYCSCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203888-A1 | Chromophores | WELLCOME TRUST LIMITED, THE (GB) | 2003-10-30 | — | — | US | disclosed |
| US-20030105130-A1 | Thiaporphyrin, selenaporphyrin, and carotenoid porphyrin compounds as c-myc and telomerase inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-06-05 | — | — | US | disclosed |
| EP-1294726-A2 | IMPROVEMENTS IN AND RELATING TO CHROMOPHORES | Catalyst Biomedica Ltd (GB) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000662-A1 | IMPROVEMENTS IN AND RELATING TO CHROMOPHORES | CATALYST BIOMEDICA LIMITED (GB) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203888-A1 | Chromophores | HCCS, PPOX, HMBS | ALDH1A1 2976/4885HPGD 1616/4885HSD17B10 625/4885 |
| US-20030105130-A1 | Thiaporphyrin, selenaporphyrin, and carotenoid porphyrin compounds as c-myc and telomerase inhibitors | MYCBP, MYC, TERF2IP | ALDH1A1 4140/4885HPGD 2936/4885HSD17B10 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.